Drug intelligence / Profile preview

1-ethoxycarbonyl-D-phe-pro-2(4-aminobutyl)hydrazine

Development stage: Unknown
Modality: Peptides, Small Molecules

Overview

1-ethoxycarbonyl-D-phe-pro-2(4-aminobutyl)hydrazine is an experimental small molecule dipeptide derivative, classified as a synthetic organic compound containing a sequence of two amino acids (D-phenylalanine and proline), with an ethoxycarbonyl group and a hydrazine moiety substituted with a 4-aminobutyl side chain. Its precise mechanism of action is not fully characterized in the public domain, but DrugBank lists prothrombin as its target, suggesting it may interact with or modulate this coagulation factor. The compound has been studied primarily in research settings and does not have established clinical indications or approvals[1].

Targets

F2 (Thrombin)

Beyond the preview

Go deeper on 1-ethoxycarbonyl-D-phe-pro-2(4-aminobutyl)hydrazine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 1-ethoxycarbonyl-D-phe-pro-2(4-aminobutyl)hydrazine.

Explore the full profile